Back to Results
First PageMeta Content
Experimental cancer treatments / Emerging technologies / Biotechnology / Oncolytic virus / Viruses / Genetically modified organism / Herpes simplex / Granulocyte macrophage colony-stimulating factor / Herpesviridae / Biology / Medicine / Molecular biology


October[removed]Summary of Licence Application DIR 132 Introduction An application has been made under the Gene Technology Act[removed]the Act) for dealings with a genetically modified organism (GMO), for use as a therapeuti
Add to Reading List

Document Date: 2015-03-06 01:37:31

Open Document

File Size: 46,61 KB

Share Result on Facebook

Company

Amgen Australia Pty Ltd / GM / PPD Pty Ltd / /

Country

United States / Canada / Australia / United Kingdom / South Africa / /

/

IndustryTerm

gene technology / pharmaceutical product / infection site / treatment of cancers / licence applications / treatment of cancer / treatment for patients with skin cancer / /

MedicalCondition

cancers / cancer / suitable solid tumours / infectious virus / cases infection / e.g. cold sore / skin cancer / tumour / persistent latent infection / disseminated disease / Primary infection / melanoma / prostate and ovarian cancers / encephalitis / infection / Parent organism Human herpes virus / Herpes simplex virus / infectious agents / Herpes simplex / metastatic melanoma / tumours / /

MedicalTreatment

chemotherapy / bone marrow transplant / surgery / immunotherapy / /

Organization

office of the Gene Technology Regulator Website / Department of Agriculture / Therapeutic Goods Administration / Australian Government / FDA / office of The Gene Technology Regulator / Gene Technology Technical Advisory Committee / /

/

Position

Governor / Environment Minister / /

Product

acyclovir / /

Technology

chemotherapy / gene technology / recombination / /

URL

www.ogtr.gov.au / /

SocialTag